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Summary
In previous studies we identified a surface molecule (termed GL183) capable of mediating cell
activation and selectively expressed by a subset of human CD3-CD16+ natural killer (NK) cells.
In this study we analyzed whether other subset-specific functional molecules were expressed in
GL183 - NK cells. To this end, mice were immunized with the PE29 (CD3- CD16+GL183 - )
NK clone. Monoclonal antibodies (mAbs) were selected by screening the hybridoma supernatants
for theirability to trigger the cytolytic activity ofclone PE29 against the human myelomonocytic
leukemia U937. The EB6 mAb (IgGI) triggered the PE29 clone, but not a GL183+ clone used
as a control. EB6+ cells ranged between 1 and 13% of peripheral blood lymphocytes and were
largely included in the CD3"CD16+CD56+ cell populations (only <2% of EB6+ cells were
CD3+). Analysis of resting or activated CD3-CD16+ populations, or clones for the expression
ofEB6 or GL183 mAbs, allowed us to identify four distinct, phenotypically stable, NK subsets
(EB6+GL183 - ; EB6+GL183+; EB6 -GL183+ ; EB6 -GL183 - ). Similar to GL183 mAb, the EB6
mAb selectively triggered the NK subset expressing the corresponding surface antigen to lyse
human tumor cell lines including U937, IGROVI, M14, and A549. In addition, EB6 mAb
sharply inhibited the cytolytic activity of EB6+ clones against P815, M12, and P3U1 murine
target cells. In EB6+GL183+ ("double-positive") clones both EB6 and GL183 mAb inhibited
the redirected killing of P815 cells induced by anti-CD16, anti-CD2 mAbs and phytohemagglutinin
(PHA). Similar to GL183 molecules, molecules precipitated by EB6 mAb were represented by
either single 58-kD chain or double chains of 55 and 58 kD (with no detectable differences in
EB6IGL183- or EB6+GL183+ clones). In sequential immunoprecipitation experiments using
the double-positive clones CEG52 and CA25.50, preclearing of cell lysates with EB6 or GL183
mAb removed only EB6 or GL183 molecules, respectively, thus indicating that the two antigenic
determinants are carried by two distinct molecules. Peptide map analysis indicated that EB6 (or
GL183) molecules precipitated from double-positive clones were identical to the corresponding
molecules isolated from single-positive ones. On the other hand, comparison of the E136 and
GL183 maps revealed peptides that were unique to each molecule, although most of the major
peptides migrated to identical positions. We further investigated whether correlation existed between
the phenotypic assignment of NK clones and their ability to mediate specific lysis of normal
allogeneic cells. All mixed lymphocyte culture-derived NK clones displaying the previously defined
"1 anti-A" specificity expressed the EB6+GL183 - surface phenotype. In addition, among
peripheral blood-derived CD3 -CD16+ clones (with PHA and IIr2), only those expressing the
EB6+GL183 - phenotype specifically lysed PHA blasts susceptible to lysis by "1 anti-A" clones.
Finally, in individuals susceptible to lysis by "1 antiA" alloreactive clones, EB6+GL183 - NK
cells (which would represent autoreactive cells) were virtually absent.
1589
￿
J. Exp. Med. ® The Rockefeller University Press - 0022-1007/90/12/1589/10 $2.00
Volume 172 December 1990 1589-1598N atural killer (NK) cells are represented by lymphocytes
able to lyse tumor target cells through a non-MHC-
restricted type of recognition (1-7). NK cellsdo not express
surface molecules such as CD3/TCR or sIg, which function
as receptors for antigens on T or B cells, respectively (8-10).
Recently, attention has been focused on the mechanisms and
surface structures involved in NK cell activation and func-
tion. In this context, it has been shown that triggering of
CD3 - CD16+ lymphocytes can be induced by mAbs di-
rected to cell surface molecules, including CD2 and CD16
(11-15). In addition, another surface molecule, termed GL183,
has been identified, different from CD16 and CD2 molecules,
that is expressed on a subset of NK cells and selectively acti-
vates/regulates these cells (16, 17) . Functional GL183 mole-
cules are present on both resting and activated NK cells and
their expression (or lack of expression) is not modified by
cell activation, proliferation, or cloning (16).
Given the restricted distribution of GL183 molecules to
a subset of CD16* cells, we investigated whether other trig-
gering surface molecules were expressed in CD16+GL183 -
NK cells. By immunizing mice with the PE29 (GL183 - )
NK clone, we obtained a mAb (EB6) capable of triggering
the immunizing clone, which selectively bound to a subset
of resting or activated NK cells or clones. Both biochemical
and functional analyses revealed that the EB6-reactive mole-
cules shared most of their properties with the GL183 mole-
cules. Although the two molecules appear to belong to the
same family, they are clearly distinct as indicated by their cell
distribution and by a number ofbiochemical evidences. The
expression (or lack of expression) of EB6 or GL183 mole-
cules allows us to identify four distinct, phenotypically stable
subsets of NK cells. Importantly, a striking correlation could
be established between one of these subsets and the ability
to specifically recognize a given NK-defined alloantigen re-
cently identified on normal lymphocytes (18-20).
Materials and Methods
Isolation and Cloning ofCD3- CD16*CD56* Lymphocytes.
￿
PBL
from normal volunteerswere isolatedby Ficoll-Hypaque gradients
and subsequently separated into different subsets by cell sorting
and/or treatment with mAbs followed by complement depletion
(18). To obtain purified GL183 * or EB6* cells from PBL, cells
were stained with the appropriate mAb followed by an isotype-
specific (anti-IgGl) rabbit anti-mouse fluoresceinated antiserum
(Southern Biotechnology Associates, Birmingham, AL) as a second
reagent (16). Purified CD16' cells were sorted using the KDl
anti-CD16 mAb and a fluoresceinated anti-IgG2a second reagent
(16). The CD3-EB6- cell subset was obtained by treatment of
PBL with anti-CD3 (OKT3) and anti-CD4 (CK79) mAbs followed
by complement depletion. The resulting CD3-CD4- population
was then stained with EB6 mAb as described above and EB6- cells
were isolated by sterile sorting as previouslydescribed (21). Cloning
of the various cell subsets was performed under limiting dilution
conditions in the presence of irradiated feeder cells, 0.1% PHA
(Gibco Limited, Paisley, Scotland), and a source ofexogenous 11,2
(rlIL2; Cetus Corp., Emeryville, CA) as previouslydescribed for
both T and NK cells (18, 22, 23). MLC-derived CD3-CD16*
clones were cultured as previously described in detail (18-20). Clones
were maintained in culture for periods of time varying from 1 to
6 mo in the presence of 100 U/ml ofrI1,2 at a cell concentration
of -106/ml in 96 round-bottomed microwells (Greiner Labor
Technik, Nurtinger, FRG).
Production ofEB6 mAb
￿
5-wk-old male BALB/c mice were im-
munized with a cell clone termed PE29 (surface phenotype:
CD3'CD16 *CD56 * GL183-) as previously described (24). The
immunization schedule consisted of 2-wk intravenous injections
of 10' PE29 cells. After six injections the mice were splenecto-
mized and immune splenocytes were fused with P3U1 myeloma
cells (24). The screening of hybridoma supernatants was based on
the ability to modulate the cytolytic function of PE29 against the
human cell line termed U937 used as "Cr-labeled target cells in
a 4-h "Cr-release assay (18). To this end, 5 x 103 PE29 cells were
cultured together with 5 x 103 U937 target cells (for a final
effector/target ratio of 1:1) in the presence of50 ul of culture su-
pernatantsderived from the various hybridomas. The assaywas per-
formed in V-bottomed microtiter trays in a final volume of 200
jul. After 4 h, 100 j,1 of supernatant was removed from each well
and counted in a gamma counter for the assessment of "Cr re-
lease. Percent specific release was determined as previouslydescribed
(21, 22). According to this screening procedure, a hybridoma, termed
EB6, whichwas able to increase the cytolytic activity ofPE29 clone
against U937 target cells, was isolated and further subcloned in
limiting dilution.
Two-color Flow Cytofluorometric Analysis.
￿
Analysis of PBL for
the distribution ofthe surface antigen recognized by the EB6 mAb
as compared with that of CD3, CD4, CD8, CD16, CD56, and
CD2 antigens was performed using two-color fluorescence
cytofluorometric analysis as previously described (25). Cells were
stained with EB6 mAb followed by FITC-conjugated (or PE-
conjugated) goat anti-mouse IgG1 antibodies (Southern Biotech-
nology Associates), and one ofthe following reagents: OKT3-PE
(IgG2a), Leu-11-FITC (IgM), KDl-FITC (IgG2a), OKT8-PE
(IgG2a), OKT4-PE (IgG2a), Leu-5-FITC (IgG2a), K218 (IgGl),
and NKH1(IgM) followed by appropriate anti-IgM PE antibodies.
OKT3, OKT8, and OKT4 mAbs were purchased from OrthoPhar-
maceutical (Raritan, NJ), whereas Leu-11 and Leu-5 were purchased
from Becton Dickinson & Co. (Basel, Switzerland). The NKHI
mAb was kindly provided by Dr. Thierry Hercend, Institut Gustave
Roussy, Villejuif, France.
FunctionalAnalysis of CD3- CD16* Clones.
￿
The cytolytic ac-
tivity of the various clones was tested in a 4-h "Cr-release assay
as described above. In all instances target cells were used at a con-
centration of 5 x 10"/ml and were represented by either human
or murine tumor cell lines or by PHAinduced lymphoblasts (18)
as described in Results. PHA blasts derived from different individ-
uals were obtained by culturing PBL for 4 d with 0.5% PHA
(vol/vol) in the presence ofrIIr2(100 U/ml). The E/T ratios ranged
from 5:1 to 0.5:1 as indicated. After titration, DEAE-Sepha-
cel-purified EB6 mAb was used in most experiments at a concen-
tration of 0.3 ng/ml resuspended in 50 I1 of medium. The other
mAbs including c288 (anti-CD16), KD1 (anti-CD16), MAR206
(anti-CD2), or GL183 were used at doses ranging from 10 to 0.2
ng/tnl dependingupon preliminary titrationexperiments. In cyto-
lytic experiments, EB6 mAb and/or the above mentioned mAbs
were added at the onset of the culture together with effector and
target cells (16).
Biochemical Characterization ofthe EB6 Molecule
￿
Cloned EB6'
cells were washed five times in cold RPMI 1640, twice in PBS,
and then surface labeled with 1211 using the lactoperoxidase/glu-
cose oxidase-catalyzed iodination (26). After labeling, cells were
washed once with PBS and resuspended (in ice) for 30 min in lysis
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filtered and dialyzed with PBS. Lysates were then incubated over-
night with 20 %11 ofpacked SepharoseCNBrBeads (Pharmacia LKB,
Uppsala, Sweden) previously coupledwith purified EB6mAb.The
immunoprecipitate was eluted by boiling for 5 min in buffer con-
taining 2.3% SDS in the presence or absence of 5% 2-ME and
analyzed on11%discontinuous SDS-polyacrylamide gels (27) . For
absorption studies, cell lysates derived from '25I-labeled double-
positive clones were immunoprecipitated three times with the first
mAband then the resulting precleared cell lysate wasimmunopre-
cipitated with the secondmAb . After washing, the specific bound
material was eluted andanalyzedby SDS-PAGE as describedabove.
Western Blot Analysis.
￿
For Western blot analysis, (28) cell ly-
sates were obtained after treatment of clones in buffer containing
1% NP-40 and 0.1% SDS for 15 min at room temperature . The
supernatants were filtered and diluted 1:2 in buffer containing 2.3%
SDS then separated bySDS-PAGE and transferred to Immobilon
PMembranes (Millipore Continental WaterSystems, Bedford,MA)
in transfer buffer (0.025M Tris, 0.19M glycine, 20% methyl al-
cohol) at 50V (constant voltage) overnight at 4°C. After transfer,
membranes were blocked in TTBS (200mM Tris/HCI, pH 7.5,
0.9% NaCl, 0.05% Tween) containing 2.3% nonfat milk .
Immunoblotswere probed with purifiedmAbs diluted in TTBS-
milkbuffer for2h at room temperature, washed in thesame buffer
(four washes, 15 min each), further incubated with '~5I anti-mouse
antiserum (100,000 cpm/ml in TTBS-milk) (Amersham, UK) fol-
lowedby four washes inTTBS (15 min each), two washes in PBS
(10 min each), and one wash in distilled water. Blots were then
dried andsubjected to autoradiography using KodakXAR5 film .
FLptideMapping
￿
Two-dimensional peptide mapping analysis was
performed according to Accolla (29) . Briefly, lysates derived from
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Figure 1 .
￿
Distribution ofEB6 antigen in PBL . In these experiments, the surface expression of EB6 antigen has been evaluatedby double fluorescence
and FACS analysis. Cells were stained with FITC-OKT3 (anti-CD3) (A) or KD1 (anti-CD16) mAb followed by FITC-conjugated goat anti-mouse
IgG2a antiserum (B). Both cell suspensions were stained with EB6mAb followed by PE-conjugated goat anti-mouse IgG1 antiserum . The contour
plot was divided into quadrants representing unstained cells (lower left), cells with only red fluorescence (upper left), cells with red and green fluorescence
(upper right), and cells with only green fluorescence (lower right) . Cells stained in red (EB6" ) in this donor were 9.6%, those stained by OKT3 mAb
were 67%, and those stained by KD1 (CD16+) were 22.2% . Cells simultaneously stained by OKT3 and EB6 mAbs were <0.3% whereas virtually
all EB6+ cells expressed CD16 antigen .
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" 5I-labeled cells were immunoprecipitated with GL183 or EB6
mAbs, and the immunoprecipitated materials were separated by
SDS-PAGE and subjected to autoradiography.
Bandscorresponding to specific proteinwere cut from the dried
gel, rehydrated overnight in PBScontaining 0.1% SDS at 37°C,
andthe supernatants were filtered to remove residual pieces ofacryl-
amide. 50 lag of albumin was added as a carrier. Reduction was
performed by incubating for 30 min at room temperature with
20 mM dithiothreitol followed by alkylation with 60 mM of io-
doacetamide for 1 h at room temperature in the dark .
Proteins were recovered by precipitation in 20% TCA at 4°C
for 2h and then washed three times with cold (-20°C) acetone.
The dried protein pellet wasresuspended in 100 Pl 1% formic acid,
10% acetic acid buffer, anddigestionwith pepsin was carried out
overnight at 37°C by adding 1 ug of enzyme. Samples were then
dried under vacuum .
First dimensions were obtained by spotting side by side two
samples on silica gels. After electrophoresis in10% acetic acid, 1%
pyridin plates were cut in halfandchromatography wasperformed
at right angles in n-butanol/acetic acid/pyridine/water 75:15:50:40
(vol/vol) . The dried plates were subjected to autoradiography.
Results
The lymphocyte clone PE29 used for mouse immuniza-
tion displayed a strong cytolytic activity against several different
histologic types of tumor cell lines. This clone, which ex-
pressed the CD3 -CD16+CD56+ phenotype, was selected
because itwasnot stainedby theGL183mAb. Thehybridoma
supernatants were screened for their ability to increase the
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Bcytolytic activity of clone PE29 against the human my-
elomonocytic leukemic cell line U937 . Previous studies have
indicated that the cytolytic activity of GL183+ clones
against these target cells was highly augmented in the pres-
ence ofGL183 mAb (16). TheEB6 mAb increased the cyto-
lytic activity of clone PE29 but not of a GL183+ clone used
as control .
Distribution ofEB6 Antigen in CD3-CD16+ Populations
and Clones. Analysis by indirect immunofluorescence revealed
that cells reacting with E136mAb ranged between 1 and 13%
in PBL derived from six different donors . Next, the expres-
sion of EB6 antigen was compared with that of other lym-
phocyte surface markers in PBL . These experiments, carried
out by double immunofluorescence andFACS analysis, demon-
strated thatEB6 antigen is expressed on acell subset expressing
CD16 but lackingCD3 antigen . Only rare cells appeared to
react simultaneously with CD3 and EB6 (<2% of the total
EB6+ population) (Fig. 1) . Similar to GL183, the EB6 mol-
ecule was expressed in cells stained by anti-CD56 mAbs, while
it was lacking on CD4+ cells . In all instances, CD8 and
CD2 antigens were expressed on a fraction of the EB6+ cells
(not shown) . Thus, the distribution ofEB6 molecule in PBL
was reminiscent ofthat oftheGL183 molecule (16, 17) . How-
ever, FACS analysis by two-color fluorescence indicated that
the percentages of the CD16+GL183+ or CD16'EB6' cells
(expressed as a fraction of CD16+ cells) greatly varied in
different individuals (Fig. 2) . Moreover, when cells were stained
by a mixture of the two antibodies, the percentages of posi-
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tive cells were always less than the sum of the percentages
ofEB6+ and GL183' cells. Taken together, the above data
suggest that GL183 and EB6 mAbs recognize two distinct,
but partially overlapping, subsets of human CD16+ NK
cells. To better analyze the distribution ofthetwo molecules
in CD16+ cells, we studied a large panel of NK clones (a
direct comparison of the distribution of the two molecules
by double fluorescence and FRCS analysis was impaired by
the fact that both mAbs belong to the IgG1 subclass) . In
experiments in which CD3 -CD16+ populations were frac-
tionated into EB6+ and EB6- subsets and cloned under lim-
iting dilution, the resulting clones maintained the original
EB6+ or EB6 - surface phenotype. Thus, similar to GL183
antigen (16), the expression or lack of expression ofEB6 an-
tigen appears to be a stable phenotypic property of two dis-
tinct NK cell subsets . Subsequently, clones were derived from
purified CD3 - lymphocytes obtained from different individ-
uals and analyzed for the surface expression of GL183 and
EB6 molecules . Four distinct phenotypic groups of CD3 -
CD16+ clones could be identified: GL183+EB6- ; GL183+
EB6+ ; EB6+GL183 - ; and EB6 -GL183- . Clones represen-
tative of each group are shown in Figure 3 . Although in the
double-positive clone CA 25.50, the antigen density ofEB6
andGL183 appears to be higher than antigen density in single-
positive clones (PE 29 and CEG 5), this finding could not
be generalized to other double-positive clones. The percen-
tages of clones belonging to each group were found to be
extremely variable among different individuals . Thus, for ex-
ample, out of 162 clones derived from individual C.E ., 49
were EB6+GL183 - , whereas only 3 wereEB6 -GL183+ . 78
clones stained simultaneously by the twomAbs (double posi-
tive), and the remaining 32 were EB6-GL183- (double
negative) . On the other hand, the majority ofclones derived
GLIB3+
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￿
Flow cytofluorometric analysis of surface antigens expressed
by CD3-CD16+ clones. Cells were stained with either one of the fol-
lowing mAbs : anti-CD3 (OKT3), anti-CD16 (KD1), anti-CD56 (K218),
GL183, or EB6, as described in Materials and Methods. Fluorescein-
conjugated goat anti-mouse Ig was used as second reagent . Note that
on the basis of GL183 and EB6 antigen expression four distinct types of
NK clones can be distinguished. The four representative clones shown
are CEG5 (GL183+EB6 - ), CA.25.50 (double positive), PE29 (EB6+
GLI83- ), and CES9 (double negative) .from individual A.M. (97/128) were double negative, whereas
21 were double positive, 9 were GL183''EB6- and only 1
was EB6+GL183- . Thus, clonal analysis confirmed that the
subsets identified by EB6 and GL183 mAbs are partially over-
lapping and that the two mAbs allow us to identify four dis-
tinct subsets of human CD16+ NK cells.
EB6 mAb Selectively Triggers the NK Subset Expressing the
Corresponding Surface Antigen. EB6 mAb has been selected
according to its ability to trigger the rytolytic activity of the
immunizing PE29 clone (CD3 - CD16+GL183- ). Since the
combined use of GL183 and EB6 mAbs allows us to identify
four distinct NK subsets, we investigated the ability of the
two mAbs to trigger the rytolytic activity of clones belonging
to these subsets. A large panel of clones (>200 clones) has
been analyzed for the ability to lyse the U937 cell line either
in the absence or presence ofeither mAb. Four representative
clones are shown in Fig. 4. It is evident that EB6 mAb stimu-
lated not only the EB6+GL183 - clone (belonging to the
same subset as the PE29 clone) but also clones expressing
both EB6 and GL183 antigens. Similarly, GL183 mAb trig-
gered both GL183+EB6 - and double-positive clones. The
two mAbs failed to induce GL183 -EB6' (double-negative)
clones. Since similar results were obtained in all clones ana-
lyzed, it appears that the surface expression ofGL183 or EB6
antigen predicts the susceptibility of a given clone to stimuli
delivered by the corresponding mAbs.
We previously reported that GL183 mAb, and its F(ab)2
fragment, could enhance the rytolytic activity of GL183+
clones against a panel of human tumor cell lines of different
histotypes (16). These included both the FcyR+ U937 and
A549 (lung carcinoma) cell lines, and the Fc-yR - IGROV
(ovarian carcinoma) and M14 (melanoma) lines. Although
not shown, the EB6 mAb had a similar effect when EB6+
clones were tested against the same panel of target cells. There-
fore, lysis of human tumor cells of different origin can be
efficiently enhanced by triggering of effector cells with ei-
ther EB6 or GL183 mAbs.
QL+sa+ DOYNLE Ess+ DDONLE
EE"- POSITIVE DLIE3- NEGATIVE
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Figure 4.
￿
Enhancement ofrytolytic activity mediated by EB6 or GL183
mAbs in NK clones belonging to different subsets. Clones CEG5
(GL183+EB6-), EG2.50 (double positive), CEG76 (EB6+GL183- ), and
CES9 (double negative) were tested for rytolytic activity against slCr-
labeled U937 cells in the presence ofgraded amounts ofeither GL183 (A)
or EB6 (A) mAbs as indicated. The E/T ratios were 3:1 for clones CEG5
and EG2.50 and 1:1 for clones CEG76 and CES9.
Regulatory Role of EB6 Surface Molecules.
￿
As previously
shown, in rytolytic assays against murine target cells, GL183
mAb resulted in effects that were opposite to those observed
with human target cells (i.e., inhibitory effects) (16) . This
inhibition required the presence of FcR on target cells and
could not be mediated by the F(ab)2 fragments of the GL183
mAb. Identical results were obtained with EB6 mAb when
EB6+ clones were tested against murine target cells (in-
cluding the mastocytoma P815, the B cell lymphoma M12,
and the myeloma P3U1; (not shown).
GL183 mAb was shown to inhibit both spontaneous and
redirected killing of P815 target cells by GL183+ clones (16).
These experiments demonstrated that GL183 mAb is able
to downregulate rytolytic responses of human NK cell clones
to stimuli such as PHA, anti-CD16, and anti-CD2 mAbs.
To compare the ability of E136 and GL183 mAbs to inhibit
the redirected killing of P815 target cells, we analyzed a se-
ries of EB6+ clones (>100 clones). Fig. 5 shows a represen-
tative experimentusingthe double-positive clone T49. It can
be seen that both mAbs inhibited, in a dose-dependent fashion,
the redirected killing ofP815 cells induced by different stimuli.
No inhibition was observed with K218 (anti-CD56) or
MAR21 (anti-CD7) mAbs, which belong to the same IgG1
subclass as GL183 and EB6 mAbs (not shown). Therefore,
the effects of EB6 mAb on the rytolytic function of EB6+
clones appear to be indistinguishable from that ofGL183 mAb
on GL183+ clones.
Biochemical Characterization ofProteins Precipitated by EB6
mAll The biochemical characteristicsof the surface antigen
recognized by EB6 mAb were studied in a series of 1251 sur-
face-labeled CD16+EB6+ clones. The molecules immuno-
precipitated by EB6 mAb and analyzed by SDS-PAGE dis-
played an apparent molecular mass of -58 kD under both
reducing and nonreducing conditions (Fig. 6). In some clones
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Inhibitoryeffect ofEB6 or GL183 mAbs on the PHA or mAb-
induced redirected killing of P815 target cells. Clone T49 (double posi-
tive) was tested for rytolytic activity against s'Cr-labeled P815 target cells
in a 4-h SICr-release assay at an E/T ratio of3:1. It should be noted that
clone T49 at an effector/target ratio of 3:1 induced 18% specific lysis of
P815 target cells in the absence of added stimuli. PHA or mAbs directed
to CD16 or CD2 (both mAbs used at a concentration of 10 ng/ml) were
added at the onset of the rytolytic test either in the absence or in the pres-
ence of graded amounts of purified EB6 (A) or GL183 (A) mAbs.however, a second 55-kD band could be observed together
with the 58-kD band (not shown) . In addition, EB6 mole-
cules immunoprecipitated either from EB6+GL183- or from
double-positive clones displayed similar characteristics under
the above conditions . It is of note that no correlation existed
between the presence or the absence of the additional55-kD
band and the coexpression of GL183 antigen on EB6+ cells
(Fig . 6) . Further comparative analysis of GL183 and EB6
mAb-reactive molecules was performed by two-dimensional
PAGE . In these studies, spots corresponding to EB6 mole-
cules were found to migrate to identical positions as those
corresponding to GL183 molecules (16) . These results were
obtained in both double-positive (EB6+GL183+) and single-
positive (EB6+GL183 - or EB6-GL183+) clones (not shown) .
Since preliminary experiments showed that bothmAbs reacted
in Western blot analysis, cell lysates derived from NK clones
were analyzed for reactivity in Western blot with either one
of the two mAbs . Cell lysates derived from single-positive
clones were reactive only with the appropriate mAb whereas
the double-positive clone EG2.50 reacted with both mAbs
(Fig. 7) . These data further confirmed the lack of reactivity
of EB6+GL183- clones with GL183 mAb (and vice versa
for EB6 -GL183+ clones with EB6 mAb) . Since in double-
positive clones molecules recognized byEB6 orGL183 mAbs
were indistinguishable, we further investigated whether the
antigenic determinants defined by the two mAbs were ex-
pressed on the same oron different molecules. To define this
point, sequential immunoprecipitation experiments were per-
formed on cell lysates derived from surface-iodinated double-
positive clones CEG52 and CA25.50 (Fig . 8) . Thus, pre-
clearing of GL183-reactive molecules completely eliminated
the reactivity of cell lysates with this antibody but did not
affect the reactivity withEB6 mAb. In addition, preclearing
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￿
SDS-PAGE analysis of sur-
face molecules precipitated by EB6 or
GL183 mAbs from CD3-CD16+ clones.
5 x 10 6 cells from clone CEG76
(EB6+GL183- ; lane A), clone F25
(EB6+GL183 - ; lane B), clone CIK52
(double positive ; lanesCand D) andclone
T49 ("double positive" ; lanes E and F)
were surface labeled with 1251 using the
lactoperoxidase technique and lysed in
buffer containing 1% NP-40 . Immuno-
precipitations were performed by using
GL183 (lanes C and E) or EB6 (lanes A,
B, D, and F) mAbs coupled to protein
A-Sepharose beads . SDS-PAGE analysis
was performed under reducingconditions
using 11% acrylamidegels. Inlanes G and
H, immunoprecipitates from the double-
positive clone CA25.50 were analyzed
under non-reducing conditions (lane G,
GL183; lane H, EB6) .
of EB6-reactive molecules greatly reduced the reactivity of
cell lysates with this antibody, but not with GL183 mAb .
These experiments suggest that the antigenic determinants
recognized by EB6 mAb or GL183 mAbs are expressed on
distinct molecules also in double-positive clones.
Peptide Map Analysis ofEB6- and GL183-reactive Mole-
cules. To determine whether EB6- and GL183-reactive chains
were different with regard to their peptide structure, com-
parative peptide maps ofthe two chains were performed after
digestion with proteolytic enzymes . As shown in Fig . 9, the
peptide maps ofEB6- and GL183-reactive chains isolated from
the double-positive CEG52 clone, appear very similar when
run together in order to allow a direct comparison of the
peptides. It can be seen that most major peptides migrate
to identical positions. In contrast, at least one peptide (arrtnv)
was found in the GL183-reactive chain but not in the EB6-
reactive chain . In addition, the EB6 chain showed at least
two peptides with minimal mobility in the chromatographic
dimension that were absent in theGL183 chain . Thus, these
data confirm that GL183 and EB6 molecules are similar but
not identical .
In Fig. 9 C, we also analyzed clone CEG5 derived from
the same donor, but which expresses the GL183+EB6- sur-
face phenotype. In this clone it has been possible to obtain
a similar number ofcpm as in the double-positive clone. It
is evident that the molecules immunoprecipitated by GL183
mAb are resolved into a series of spots which are identical
to those present in Fig. 9B . Although not shown, the EB6-
specific peptides derived from the EB6+GL183 - clone
CEG76 were identical to those of Fig . 9A . Thus, the pep-
tide map comparison provides unequivocal evidence that the
EB6- and GL183-reactive chains are analogous to one another,
since they share several peptide fragments incommon . How-
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￿
Immunoblotting analysis ofEB6 and GL183 molecules inNK
clones belonging to different subsets . Total cell lysates (5 x 106 cell
equivalents per lane) derived fromthedouble-positive clone EG2.50 (lanes
A and D), the GL183*EB6 - clone CEG5 (lanes B and E), or the
EB6* GL183- clone CEG76 (lanes C and F) were separated on SDS-poly-
acrylamide gels in the absence of 2-ME . After transfer to Immobilon P
membranes, blots were probed with GL183 (Lanes A-C) or EB6 (lanes
D-F) mAbs as described in Materials and Methods.
ever, the presence of unique peptides after proteolysis ofEB6-
or GL183-reactive chains further indicates that the two mol-
ecules are not identical .
Correlation Between EB61CL183 mAb-defined NK Subsets
and Specific Lysis ofAllogeneic Cells. As previously shown,
MLC-stimulated human CD3-CD16+ NK cells display the
Figure 8 .
￿
Sequential immunoprecipitation ofEB6 and GL183 antigens
from a double-positive NK clone. 20 x 106 cells from clone CA25.50
were surface labeled and lysed as described in Materials and Methods. Cell
lysates were divided into two aliquots and immunoprecipitated with ei-
therEB6 (laneA) or GL183 (laneD) mAbs coupled toprotein A-Sepharose .
The preclearing procedure with a given mAb was repeated four times.
11116-precleared and GL183-precleared lysates were then immunoprecipi-
tated with either one of the two mAbs and analyzed in an 11% polyacryl-
amide slab gel system . EB6-precleared cell lysate immunoprecipitated with
E136 (lane B) orGL183mAb (lane C). GL183-precleared cell lysate immu-
noprecipitated with either GL183 (lane E) or EB6mAb (lane F) . In lanes
B, C, E, and F twice as much cell lysate was used as compared with lanes
A and D .
ability to specificallylyre normal allogeneic cells(PHAblasts)
derived from the stimulating donor (18) . Although several
NK-defined allospecificities appear to exist (reference 20;
Moretta, A ., E . Ciccone, O. Viale, D. Pende, G. Tripodi,
C. Bottino, andL . Moretta, manuscript in preparation), only
one has been analyzed in detail so far (20) . This allospecificity
Figure 9.
￿
Comparative analysis of the two-dimensional peptide maps of EB6 and GL183 molecules. EB6 (A) and GL183 (B) molecules purified
from the double-positive clone CEG52 were digested with pepsin. In C, the GL183 molecule isolated from GL183+EB6 - clone CEG5 is shown for
comparison. Each sample was spotted on a silica gel plate and peptides were separated by electrophoresis (verticaldimension) and chromatography (horizontal
dimension) . Note that 6,000 cpm were applied per individual sample and that A and B were run in parallel . Arrows indicate specific peptides in the
EB6 or GL183 molecules.
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￿
Moretta et al.has been defined by the use of NK clones termed "1 anti-A."
1 anti-A clones were found to lyse one out of four normal
random donors (20). In this study, we selected a series of
CD3 - CD16+ clones displaying 1 anti-A specificity (i.e.,
capable of specifically lysing appropriate normal allogeneic
PHA blasts). These clones were derived from three different
individuals resistant to lysis by 1 anti-A clones. We found
that all (over 100 clones) were characterized by the EB6+
GL183- surface phenotype. In another series of experiments,
clones were obtained directly from PBL without preselec-
tion in MLC (19). Thus, purified CD3 -CD16+ cells were
cultured underlimiting dilution in the presence ofPHA, feeder
cells, and an exogeneous source of IIr2. The clones obtained,
representative of the four different EB6/GL183 mAb-defined
NK subsets, were assessed for specific cytolytic activity against
"Cr-labeled PHA-blasts derived from donors that were ei-
ther susceptible or resistant to lysis by 1 anti-A clones (20).
As shown in Fig. 10, only clones expressing the EB6+
GL183 - phenotype were able to specifically lyse 1 anti-A-
susceptible target cells. More importantly, only 1 of 18 clones
expressing the EB6+GL183- surface phenotype failed to lyse
these target cells. Similar results were obtained by the anal-
ysis of clones derived from two additional donors. In agree-
ment with previous results (18), these clones did not lyse au-
tologous or allogeneic PHA blasts previously characterized
as resistant to lysis by 1 anti-A clones.
The abovedata suggest that, in different donors, most cells
belonging to the EB6+GL183 - NK subset may be capable
of lysing 1 anti-A-susceptible target cells. If this holds true,
in donors carrying the 1 anti-A specificity, EB6+GL183 -
cells would represent a potentially autoreactive subset. To ex-
plore this possibility, we analyzed the EB6/GL183 surface
phenotype ofclones derived from such donors. In all of these
individuals, clones expressing the EB6+GL183 - phenotype
aL1B3+ DOUBLE EBB+ DOUBLE
EBB- POSITIVE GL,B3- NEGATIVE
Figure 10.
￿
Specific lysis of normal allogeneic cells by EB6+GL183-
clones. Clones derived from peripheral blood CD3 - lymphocytes ofdonor
1 (E.C.) were tested for 1 anti-A cytolytic activity against PHAinduced
lymphoblasts derived from donor A.M. Each point corresponds to the
cytolytic activitymediatedby a single clone. Clones belonging to different
subsets are represented in different quadrants. Note that only EB6+
GL183- clones displayed 1 anti-A specificity.
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were extremely rare or absent, whereas they represent 20-40%
of CD3 -CD16+ clones derived from 1 anti-A-resistant
donors. For example, they represented only 1 out of 128
CD3-CD16+ clones derived from donor A.M. In addition,
this clone failed to lyse 1 anti-A-susceptible target cells. It
should be noted that these results at the clonal level are con-
sistent with data reported in Fig. 2 (donor A.M.). Indeed
in this donor, the proportion of peripheral blood CD16+
cells expressing GL183 antigen was similar to that of cells
stained by a mixture of GL183 and E136 mAbs. These data
already suggested that the small proportion of CD16+EB6+
cells was almost entirely represented by double-positive
(GL183+EB6+) cells.
Discussion
In the present study we describe a novel surface molecule
(EB6) expressed by a subset ofhuman NK cells that mediates
cell triggering. The EB6 molecule is functionally and struc-
turally related to the previously described GL183 molecule
(16, 17). At least four different NK cell subsets could be
identifiedon the basis of the expression ofEB6 and/or GL183
molecules. More importantly, a direct correlation has been
found between a given phenotypically defined NK cell subset
and its ability to specifically recognize normal allogeneic cells.
Our previous studies revealed the existence, at the NK cell
surface, of a functional molecule (GL183) that, different from
other molecules involved in CD3 - CD16+ cell activation,
(i.e., CD16 and CD2), defined a subset of NK cells. The ex-
pression or lack of expression of GL183 surface molecules
represents a stable phenotypic property of NK cells, as the
GL183+ or GL183 - phenotype of freshly derived CD3 -
CD16+ cells was maintained after cell culture, exposure to
lymphokines, and clonal expansion (16). Another important
feature of GL183 surface antigen was its ability to exert a
regulatory role in the control of cell activation induced by
different stimuli, including anti-CD16 mAb, anti-CD2, and
PHA. The newly identified E136 molecule shares most of the
structural and functional propertiesof GL183 molecules. How-
ever, a series of experimental evidences clearly indicated that
the two molecules are distinct and define NK cell subsets
that are only partially overlapping. First, it should be noted
that the E136 mAb was obtained against the PE29 clone that
did not express detectable GL183 molecules. This clone was
subsequently found to be representative of an NK subset ex-
pressing the EB6+GL183 - surface phenotype. Clonal anal-
ysis also demonstrated that the E136 molecule is expressed
in some GL183+ cells, thus defining a subset coexpressing
EB6 and GL183 molecules (double positive). In addition,
GL183 molecules are also present in cells that lack surface
expression of EB6 (GL183+EB6 - subset). Finally, a fourth
subset of CD3 - CD16+ cells could be defined by the simul-
taneous lack of reactivity with the two mAbs. The finding
that double-positive clones reacted with the two mAbs raised
the question of whether the antigenic determinants recog-
nized by EB6 or GL183 mAbs represented two different epi-
topes expressed by a single (polymorphic) molecule or rather
by distinct surface molecules. Preclearing of cell lysates de-
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0rived from double-positive clones with either one ofthe two
mAbs did not remove molecules recognized by the other mAb,
thus indicating that the two mAbs react with distinct sur-
face molecules. In addition, peptide map analysis ofthe mol-
ecules precipitated by GL183 or EB6 mAbs from double-
positive or GL183+EB6 - or EB6IGL183 - clones, revealed
the existence of unique peptides in each molecule, thus
confirming that, in spite of the biochemical and functional
similarities, the two molecules are different. However, pep-
tide map analysis also shows that GL183 and EB6 molecules
share the majority of the peptides, thus suggesting that they
belong to the same family. Since double-positive clones simul-
taneously express EB6 and GL183 molecules, one may spec-
ulate that NK clones presently defined as single positive also
may actually express an additional chain ("x chains") belonging
to the same molecular family. According to this hypothesis,
at least some double-negative NK cellsmay express two still-
undefined members of this molecular species.
Having recently demonstrated that NK cells can specifically
recognize allogeneic cells (18-20), we investigated whether
a relationship existed between thisfunction and the expres-
sion ofEB6 and/or GL183 molecules. We found that the NK-
defined allospecificity that had been termed 1 anti-A (20) dis-
played a striking correlation with one of these subsets. Thus,
all the MLC-derived CD3- CD16+ clones displaying 1 anti-A
specificity were characterized by the EB6+GL183 - surface
phenotype. In addition, virtually all EB6+GL183 - clones
derived directly from PBL (without preselection in MLC)
were found to lyse 1 anti-A-susceptible target cells. These
data are reminiscent of a recent report in mice in which a
mAb-defined subset of NK cells mediated the rejection of
incompatible Hh-1-d bone marrow graft (30).
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